Sentry Bioconvertible IVC filter two-year results show zero tilt or migration


Two-year results for the SENTRY trial were presented at the Vascular Interventional Advances conference (VIVA; 5–8 November, Las Vegas, USA). The prospective, multicentre trial of the Sentry (BTG), a bioconvertible IVC filter, found that in addition to providing protection against pulmonary embolism during the transient risk period, the device also had zero instances of tilt, perforation, migration and embolisation through two years of imaging-intensive follow-up.

“The trial shows no device-related pulmonary embolism and zero stability complications. Physicians can have the peace of mind that they are protecting their patients from the devastating consequences of PE while reducing complications often associated with IVC filter retrieval. This device eliminates the need to retrieve and that truly makes it a next-generation device,” says BTG chief commercial officer John Sylvester.

The findings were presented by principal investigator Michael Dake (Stanford, USA). In the long-term data, 85 patients were followed for 24 months using computed tomography (CT) or CT venography imaging. The rate of freedom from new symptomatic pulmonary embolism through 60 days was 100% and there continued to be no cases of device-related new symptomatic pulmonary embolism through 24 months.

The results, as reported at VIVA, showed that there were no instances of filter tilt, migration, embolisation, fracture or IVC perforation through 24-months. Two patients developed symptomatic caval thrombosis during the first month, however neither experienced recurrence after successful interventions and no further instances of symptomatic caval thrombosis occurred at 24 months. Filter bioconversion was successful for 95.7% of patients at six months, 96.4% at 12 months, and 96.5% at 24 months. No IVC stenosis was reported.


Please enter your comment!
Please enter your name here